Clinical Trial Update: Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety update for immediate-release tolvaptan in autosomal dominant polycystic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycystic Kidney Disease Autosomal Dominant

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Polycystic Kidney, Autosomal Dominant | Phase 3 | Status: COMPLETED | Results posted: 2019-11-27